# US 2024/0199616 A1 · Bicyclic compounds as allosteric shp2 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199616 A1
- Document ID: US20240199616A1
- Status: Published application
- Kind: A1
- Application number: 18/220,196
- Filed: 2023-07-10
- Published: 2024-06-20
- Earliest claimed: 2017-01-23
- Assignees: Revolution Medicines, Inc.
- Applicants: Revolution Medicines, Inc.
- Inventors: Brian R. BLANK; Jennifer PITZEN; Gang WANG; Walter S. WON; Christos TZITZILONIS; Jie Jack LI; Elena S. KOLTUN; Naing AAY; Andreas BUCKL; Kevin MELLEM; Christopher SEMKO; Ash JOGALEKAR; Gert KISS; Adrian GILL
- Web page: https://patentgrep.com/patent/US20240199616A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D 471/04: Ortho-condensed systems
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 498/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.

## Claims

### Claim at position 1

-87. (canceled)

### Claim 88

A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula IV:
or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:
wherein ring B is optionally substituted on any available carbon with one or two substituents independently selected from the group consisting of —C1-C6 alkyl, —CH2F, —CHF2, —CF3, —(CH2)nNH2, —(CH2)nOH, heterocyclyl, and heteroaryl;
R2 is —H, halogen, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —NR5R6, —OH, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, or heterocyclyl;
wherein the heterocyclyl contains 1, 2, 3, 4, or 5 heteroatoms independently selected from the group consisting of nitrogen, phosphorus, oxygen, and sulfur;
wherein the heterocyclyl is not attached via a nitrogen atom;
wherein the —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, or heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —CN, —NO2, —NR5R6, —NR5S(O)R6, —NR5S(O)NR5R6, —NR5S(O)2R6, —NR5S(O)2NR5R6, —OR5, ═O, —SR5, —S(O)R5, —S(O)NR5R6, —S(O)2R5, —S(O)2NR5R6, heterocyclyl, aryl, heteroaryl, and —R5;
Y2 is —NRa—, —NRaC(O)—, —NRaC(O)N(Ra)—, —NRaC(O)O—, —NRaC(S)—, —NRaC(S)NRa—, or —NRaS(O)2—, wherein the bond on the left side of Y2 is bound to the ring and the bond on the right side of Y2 is bound to R3;
R3 and Ra, together with the atom(s) to which they are attached, form a monocyclic or polycyclic 3- to 12-membered heterocyclyl or a spirocyclic 5- to 12-membered heterocyclyl;
wherein the monocyclic or polycyclic 3- to 12-membered heterocyclyl or spirocyclic 5- to 12-membered heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of —C1-C6 alkyl, —CH2F, —CHF2, —CF3, —(CH2)nNH2, —(CH2)nOH, ═O, heterocyclyl, and heteroaryl;
R4 is
wherein:
Y1 is a direct bond, —CH2—, —C(═CH2)—, —NH—, —S—, —S(O)—, —S(O)2—, or —S(O)2NH—;
ring A is a monocyclic or polycyclic 5- to 12-membered cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and
each R1 is independently —H, —D, halogen, —CN, —NO2, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C(O)R5, —C(O)OR5, —NR5R6, —NR5S(O)R6, —NR5S(O)NR5R6, —NR5S(O)2R6, —NR5S(O)2NR5R6, —OR5, —SR5, S(O)R5, —S(O)NR5R6, —S(O)2R5, —S(O)2NR5R6, —C3-C8 cycloalkyl, or —C4-C8 cycloalkenyl;
wherein each —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C3-C8 cycloalkyl, and —C4-C8 cycloalkenyl is optionally and independently substituted with one or more substituents independent selected from the group consisting of halogen, —CN, —NO2, —NR5R6, —NR5S(O)R6, —NR5S(O)NR5R6, —NR5S(O)2R6, —NR5S(O)2NR5R6, —OR5, ═O, —SR5, —S(O)R5, —S(O)NR5R6, —S(O)2R5, —S(O)2NR5R6, heterocyclyl, aryl, heteroaryl, and —R5;
each R5 is independently —H, —D, halogen, —CN, —NO2, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —NR7R8, —OR7, —SR7, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, or a monocyclic or polycyclic 3- to 12-membered heterocyclyl;
each R6 is independently —H, —D, halogen, —CN, —NO2, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —NR7R8, —OR7, —SR7, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, or a monocyclic or polycyclic 3- to 12-membered heterocyclyl;
each R7 is independently —H, —D, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, or a monocyclic or polycyclic 3- to 12-membered heterocyclyl;
wherein each —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, and monocyclic or polycyclic 3- to 12-membered heterocyclyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of —CN, —NO2, —NH2, —OH, and —SH;
each R8 is independently —H, —D, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, or a monocyclic or polycyclic 3- to 12-membered heterocyclyl;
wherein each —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, and monocyclic or polycyclic 3- to 12-membered heterocyclyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of —CN, —NO2, —NH2, —OH, and —SH;
each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
with the provisos that:
(1) the heteroaryl ring of A is not furanyl or thiophenyl; and
(2) Ra and R3, together with the atom(s) to which they are attached, do not form an optionally substituted piperazinyl.

### Claim 89 (depends on 88)

The method of claim 88, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.

### Claim at position 4

-92. (canceled)

### Claim 93

A method of treating a disease associated with SHP2 modulation in a subject in need thereof, comprising administering to the subject an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula IV:
or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:
is:
wherein ring B is optionally substituted on any available carbon with one or two substituents independently selected from the group consisting of —C1-C6 alkyl, —CH2F, —CHF2, —CF3, —(CH2)nNH2, —(CH2)nOH, heterocyclyl, and heteroaryl;
R2 is —H, halogen, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —NR5R6, —OH, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, or heterocyclyl;
wherein the heterocyclyl contains 1, 2, 3, 4, or 5 heteroatoms independently selected from the group consisting of nitrogen, phosphorus, oxygen, and sulfur;
wherein the heterocyclyl is not attached via a nitrogen atom;
wherein the —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, or heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —CN, —NO2, —NR5R6, —NR5S(O)R6, —NR5S(O)NR5R6, —NR5S(O)2R6, —NR5S(O)2NR5R6, —OR5, ═O, —SR5, —S(O)R5, —S(O)NR5R6, —S(O)2R5, —S(O)2NR5R6, heterocyclyl, aryl, heteroaryl, and —R5;
Y2 is —NRa—, —NRaC(O)—, —NRaC(O)N(Ra)—, —NRaC(O)O—, —NRaC(S)—, —NRaC(S)NRa—, or —NRaS(O)2—, wherein the bond on the left side of Y2 is bound to the ring and the bond on the right side of Y2 is bound to R3;
R3 and Ra, together with the atom(s) to which they are attached, form a monocyclic or polycyclic 3- to 12-membered heterocyclyl or a spirocyclic 5- to 12-membered heterocyclyl;
wherein the monocyclic or polycyclic 3- to 12-membered heterocyclyl or spirocyclic 5- to 12-membered heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of —C1-C6 alkyl, —CH2F, —CHF2, —CF3, —(CH2)nNH2, —(CH2)nOH, ═O, heterocyclyl, and heteroaryl;
R4 is
wherein:
Y1 is a direct bond, —CH2—, —C(═CH2)—, —NH—, —S—, —S(O)—, —S(O)2—, or —S(O)2NH—;
ring A is a monocyclic or polycyclic 5- to 12-membered cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and
each R1 is independently —H, —D, halogen, —CN, —NO2, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C(O)R5, —C(O)OR5, —NR5R6, —NR5S(O)R6, —NR5S(O)NR5R6, —NR5S(O)2R6, —NR5S(O)2NR5R6, —OR5, —SR5, S(O)R5, —S(O)NR5R6, —S(O)2R5, —S(O)2NR5R6, —C3-C8 cycloalkyl, or —C4-C8 cycloalkenyl;
wherein each —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C3-C8 cycloalkyl, and —C4-C8 cycloalkenyl is optionally and independently substituted with one or more substituents independent selected from the group consisting of halogen, —CN, —NO2, —NR5R6, —NR5S(O)R6, —NR5S(O)NR5R6, —NR5S(O)2R6, —NR5S(O)2NR5R6, —OR5, ═O, —SR5, —S(O)R5, —S(O)NR5R6, —S(O)2R5, —S(O)2NR5R6, heterocyclyl, aryl, heteroaryl, and —R5;
each R5 is independently —H, —D, halogen, —CN, —NO2, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —NR7R8, —OR7, —SR7, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, or a monocyclic or polycyclic 3- to 12-membered heterocyclyl;
each R6 is independently —H, —D, halogen, —CN, —NO2, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —NR7R8, —OR7, —SR7, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, or a monocyclic or polycyclic 3- to 12-membered heterocyclyl;
each R7 is independently —H, —D, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, or a monocyclic or polycyclic 3- to 12-membered heterocyclyl;
wherein each —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, and monocyclic or polycyclic 3- to 12-membered heterocyclyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of —CN, —NO2, —NH2, —OH, and —SH;
each R8 is independently —H, —D, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, or a monocyclic or polycyclic 3- to 12-membered heterocyclyl;
wherein each —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —C3-C8 cycloalkyl, —C4-C8 cycloalkenyl, and monocyclic or polycyclic 3- to 12-membered heterocyclyl is optionally and independently substituted with one or more substituents independently selected from the group consisting of —CN, —NO2, —NH2, —OH, and —SH;
each n is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
with the provisos that:
(1) the heteroaryl ring of A is not furanyl or thiophenyl; and
(2) Ra and R3, together with the atom(s) to which they are attached, do not form an optionally substituted piperazinyl.

### Claim 94 (depends on 93)

The method of claim 93, wherein the disease is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.

### Claim at position 7

-97. (canceled)

### Claim 98 (depends on 88)

The method of claim 88, wherein ring B is optionally substituted on any available carbon with one or two substituents independently selected from the group consisting of —C1-C6 alkyl, —CH2F, —CHF2, —CF3, —(CH2)nNH2, and —(CH2)˜ OH.

### Claim 99 (depends on 88)

The method of claim 88, wherein R2 is —C1-C6 alkyl; and
wherein the —C1-C6 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —NR5R6, and —OR5.

### Claim 100 (depends on 88)

The method of claim 88, wherein R2 is —CH3.

### Claim 101 (depends on 88)

The method of claim 88, wherein Y2 is —NRa—, wherein the bond on the left side of Y2 is bound to the ring and the bond on the right side of the Y2 moiety is bound to R3.

### Claim 102 (depends on 88)

The method of claim 88, wherein R3 and Ra, together with the atom(s) to which they are attached, form a monocyclic or polycyclic 3- to 12-membered heterocyclyl; and
wherein the monocyclic or polycyclic 3- to 12-membered heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of —C1-C6 alkyl, —CH2F, —CHF2, —CF3, —(CH2)nNH2, and —(CH2)nOH.

### Claim 103 (depends on 88)

The method of claim 88, wherein R3 and Ra, together with the atom(s) to which they are attached, form a spirocyclic 5- to 12-membered heterocyclyl; and
wherein the spirocyclic 5- to 12-membered heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of —C1-C6 alkyl, —CH2F, —CHF2, —CF3, —(CH2)nNH2, and —(CH2)nOH.

### Claim 104 (depends on 103)

The method of claim 103, wherein the spirocyclic 5- to 12-membered heterocyclyl is optionally substituted with one or more independently selected —C1-C6 alkyl substituents.

### Claim 105 (depends on 103)

The method of claim 103, wherein the spirocyclic 5- to 12-membered heterocyclyl is optionally substituted with one or more independently selected —NH2 substituents.

### Claim 106 (depends on 88)

The method of claim 88, wherein Y1 is a direct bond.

### Claim 107 (depends on 88)

The method of claim 88, wherein Y1 is —S—.

### Claim 108 (depends on 88)

The method of claim 88, wherein ring A is a monocyclic or polycyclic aryl.

### Claim 109 (depends on 88)

The method of claim 88, wherein ring A is a monocyclic or polycyclic heteroaryl.

### Claim 110 (depends on 88)

The method of claim 88, wherein each R1 is independently —H, halogen, or —NR5R6.

### Claim 111 (depends on 88)

The method of claim 88, wherein the compound is of Formula IV-Q:
or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:
is:
wherein ring B is optionally substituted on any available carbon with one or two substituents independently selected from the group consisting of —C1-C6 alkyl, —CH2F, —CHF2, —CF3, —(CH2)nNH2, and —(CH2)nOH;
R2 is —H, —C1-C6 alkyl, —NR5R6, or —OH;
wherein the —C1-C6 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —NR5R6, and OR5;
Y2 is —NRa—, wherein the bond on the left side of Y2 is bound to the ring and the bond on the right side of the Y2 moiety is bound to R3;
R3 and Ra, together with the atom(s) to which they are attached, form a monocyclic or polycyclic 3- to 12-membered heterocyclyl or a spirocyclic 5- to 12-membered heterocyclyl;
wherein the monocyclic or polycyclic 3- to 12-membered heterocyclyl or spirocyclic 5- to 12-membered heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of —C1-C6 alkyl, —CH2F, —CHF2, —CF3, —(CH2)nNH2, and —(CH2)nOH;
R4 is
wherein:
Y1 is a direct bond or —S—;
ring A is a monocyclic or polycyclic aryl or heteroaryl; and
each R1 is independently —H, halogen, —CN, —C1-C6 alkyl, —NR5R6, or OR5;
each R5 is independently —H or —C1-C6 alkyl; and
each R6 is independently —H or —C1-C6 alkyl.

### Claim 112 (depends on 88)

The method of claim 88, wherein the compound, or a stereoisomer thereof, is selected from the group consisting of:
or a pharmaceutically acceptable salt or tautomer thereof.

### Claim 113 (depends on 88)

The method of claim 88, wherein the compound, or a stereoisomer thereof, is selected from the group consisting of:
or a pharmaceutically acceptable salt or tautomer thereof.

### Claim 114 (depends on 93)

The method of claim 93, wherein ring B is optionally substituted on any available carbon with one or two substituents independently selected from the group consisting of —C1-C6 alkyl, —CH2F, —CHF2, —CF3, —(CH2)nNH2, and —(CH2)˜ OH.

### Claim 115 (depends on 93)

The method of claim 93, wherein R2 is —C1-C6 alkyl; and
wherein the —C1-C6 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —NR5R6, and —OR5.

### Claim 116 (depends on 93)

The method of claim 93, wherein R2 is —CH3.

### Claim 117 (depends on 93)

The method of claim 93, wherein Y2 is —NRa—, wherein the bond on the left side of Y2 is bound to the ring and the bond on the right side of the Y2 moiety is bound to R3.

### Claim 118 (depends on 93)

The method of claim 93, wherein R3 and Ra, together with the atom(s) to which they are attached, form a monocyclic or polycyclic 3- to 12-membered heterocyclyl; and
wherein the monocyclic or polycyclic 3- to 12-membered heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of —C1-C6 alkyl, —CH2F, —CHF2, —CF3, —(CH2)nNH2, and —(CH2)˜ OH.

### Claim 119 (depends on 93)

The method of claim 93, wherein R3 and Ra, together with the atom(s) to which they are attached, form a spirocyclic 5- to 12-membered heterocyclyl; and
wherein the spirocyclic 5- to 12-membered heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of —C1-C6 alkyl, —CH2F, —CHF2, —CF3, —(CH2)nNH2, and —(CH2)nOH.

### Claim 120 (depends on 119)

The method of claim 119, wherein the spirocyclic 5- to 12-membered heterocyclyl is optionally substituted with one or more independently selected —C1-C6 alkyl substituents.

### Claim 121 (depends on 119)

The method of claim 119, wherein the spirocyclic 5- to 12-membered heterocyclyl is optionally substituted with one or more independently selected —NH2 substituents.

### Claim 122 (depends on 93)

The method of claim 93, wherein Y1 is a direct bond.

### Claim 123 (depends on 93)

The method of claim 93, wherein Y1 is —S—.

### Claim 124 (depends on 93)

The method of claim 93, wherein ring A is a monocyclic or polycyclic aryl.

### Claim 125 (depends on 93)

The method of claim 93, wherein ring A is a monocyclic or polycyclic heteroaryl.

### Claim 126 (depends on 93)

The method of claim 93, wherein each R1 is independently —H, halogen, or —NR5R6.

### Claim 127 (depends on 93)

The method of claim 93, wherein the compound is of Formula IV-Q:
or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein:
is:
wherein ring B is optionally substituted on any available carbon with one or two substituents independently selected from the group consisting of —C1-C6 alkyl, —CH2F, —CHF2, —CF3, —(CH2)nNH2, and —(CH2)nOH;
R2 is —H, —C1-C6 alkyl, —NR5R6, or —OH;
wherein the —C1-C6 alkyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, —NR5R6, and OR5;
Y2 is —NRa—, wherein the bond on the left side of Y2 is bound to the ring and the bond on the right side of the Y2 moiety is bound to R3;
R3 and Ra, together with the atom(s) to which they are attached, form a monocyclic or polycyclic 3- to 12-membered heterocyclyl or a spirocyclic 5- to 12-membered heterocyclyl;
wherein the monocyclic or polycyclic 3- to 12-membered heterocyclyl or spirocyclic 5- to 12-membered heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of —C1-C6 alkyl, —CH2F, —CHF2, —CF3, —(CH2)nNH2, and —(CH2)nOH;
R4 is
wherein:
Y1 is a direct bond or —S—;
ring A is a monocyclic or polycyclic aryl or heteroaryl; and
each R1 is independently —H, halogen, —CN, —C1-C6 alkyl, —NR5R6, or OR5;
each R5 is independently —H or —C1-C6 alkyl; and
each R6 is independently —H or —C1-C6 alkyl.

### Claim 128 (depends on 93)

The method of claim 93, wherein the compound, or a stereoisomer thereof, is selected from the group consisting of:
or a pharmaceutically acceptable salt or tautomer thereof.

### Claim 129 (depends on 93)

The method of claim 93, wherein the compound, or a stereoisomer thereof, is selected from the group consisting of:
or a pharmaceutically acceptable salt or tautomer thereof.
